JPWO2020012337A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020012337A5 JPWO2020012337A5 JP2021500409A JP2021500409A JPWO2020012337A5 JP WO2020012337 A5 JPWO2020012337 A5 JP WO2020012337A5 JP 2021500409 A JP2021500409 A JP 2021500409A JP 2021500409 A JP2021500409 A JP 2021500409A JP WO2020012337 A5 JPWO2020012337 A5 JP WO2020012337A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- dione
- methyl
- cyclohexyl
- piperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 (5-((2- (Ethylamino) cyclohexyl) amino) -1-oxoisoindoline-2-yl) piperidine-2,6-dione Chemical compound 0.000 claims description 205
- 229910052757 nitrogen Inorganic materials 0.000 claims description 77
- 125000005842 heteroatom Chemical group 0.000 claims description 64
- 229910052717 sulfur Inorganic materials 0.000 claims description 62
- 229910052760 oxygen Inorganic materials 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000001188 haloalkyl group Chemical group 0.000 claims description 44
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- 239000000651 prodrug Substances 0.000 claims description 28
- 229940002612 prodrug Drugs 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 20
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims description 17
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims description 17
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000004677 hydrates Chemical class 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 9
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 8
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- PRGCLFLBCUVASG-OWZOALSMSA-N 3-[6-[methyl-[(1R,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@@H](CCCC1)NC PRGCLFLBCUVASG-OWZOALSMSA-N 0.000 claims description 4
- 208000003200 Adenoma Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 108091092878 Microsatellite Proteins 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 210000000115 thoracic cavity Anatomy 0.000 claims description 4
- OVUUENFQYGSZAZ-KSCSMHSMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-(methylamino)cyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CCC1)NC)C)=O)=O OVUUENFQYGSZAZ-KSCSMHSMSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- JJBKBZHMNAQABU-NQUCAWMESA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2R)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@@H](C2=CC=CC=C2C1)NCC)=O)=O JJBKBZHMNAQABU-NQUCAWMESA-N 0.000 claims description 2
- XAZCHEVDICQBSX-ZAWSQKNBSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2R)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@@H](CC2=CC=CC=C12)NCC)=O)=O XAZCHEVDICQBSX-ZAWSQKNBSA-N 0.000 claims description 2
- QCRHWBLMWLLUMA-OWZOALSMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2R)-2-(ethylamino)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@@H](CCCC1)NCC)=O)=O QCRHWBLMWLLUMA-OWZOALSMSA-N 0.000 claims description 2
- JJBKBZHMNAQABU-VDZZXDNDSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2S)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@@H](C2=CC=CC=C2C1)NCC)=O)=O JJBKBZHMNAQABU-VDZZXDNDSA-N 0.000 claims description 2
- XAZCHEVDICQBSX-PWKISDLSSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2S)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@H](CC2=CC=CC=C12)NCC)=O)=O XAZCHEVDICQBSX-PWKISDLSSA-N 0.000 claims description 2
- QCRHWBLMWLLUMA-MYFVLZFPSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1R,2S)-2-(ethylamino)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@H](CCCC1)NCC)=O)=O QCRHWBLMWLLUMA-MYFVLZFPSA-N 0.000 claims description 2
- JJBKBZHMNAQABU-VRAFCGOGSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2R)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@H]1[C@H](C2=CC=CC=C2C1)NCC)=O)=O JJBKBZHMNAQABU-VRAFCGOGSA-N 0.000 claims description 2
- XAZCHEVDICQBSX-OBIJOXKXSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2R)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@@H](CC2=CC=CC=C12)NCC)=O)=O XAZCHEVDICQBSX-OBIJOXKXSA-N 0.000 claims description 2
- QCRHWBLMWLLUMA-DVKDBIPTSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2R)-2-(ethylamino)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@@H](CCCC1)NCC)=O)=O QCRHWBLMWLLUMA-DVKDBIPTSA-N 0.000 claims description 2
- JJBKBZHMNAQABU-BXBRYHBFSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2S)-1-(ethylamino)-2,3-dihydro-1H-inden-2-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@H](C2=CC=CC=C2C1)NCC)=O)=O JJBKBZHMNAQABU-BXBRYHBFSA-N 0.000 claims description 2
- XAZCHEVDICQBSX-DJJOMLBWSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2S)-2-(ethylamino)-2,3-dihydro-1H-inden-1-yl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@H](CC2=CC=CC=C12)NCC)=O)=O XAZCHEVDICQBSX-DJJOMLBWSA-N 0.000 claims description 2
- QCRHWBLMWLLUMA-UBFHEZILSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[(1S,2S)-2-(ethylamino)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)[C@@H]1[C@H](CCCC1)NCC)=O)=O QCRHWBLMWLLUMA-UBFHEZILSA-N 0.000 claims description 2
- XAPDABIVVXYPFR-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[2-(3-ethoxyazetidin-1-yl)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)C1C(CCCC1)N1CC(C1)OCC)=O)=O XAPDABIVVXYPFR-UHFFFAOYSA-N 0.000 claims description 2
- NKHRXESEEASGFS-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[2-(3-ethoxyazetidin-1-yl)cyclopentyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)C1C(CCC1)N1CC(C1)OCC)=O)=O NKHRXESEEASGFS-UHFFFAOYSA-N 0.000 claims description 2
- QCRHWBLMWLLUMA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[[2-(ethylamino)cyclohexyl]-methylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C)C1C(CCCC1)NCC)=O)=O QCRHWBLMWLLUMA-UHFFFAOYSA-N 0.000 claims description 2
- JAYWKANBWUUEPJ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-(2-piperidin-1-ylcyclopentyl)amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1C(CCC1)N1CCCCC1)C)=O)=O JAYWKANBWUUEPJ-UHFFFAOYSA-N 0.000 claims description 2
- VDKPJIVXZTYGFX-NYKYFDBJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](C2=CC=CC=C2C1)NC)C)=O)=O VDKPJIVXZTYGFX-NYKYFDBJSA-N 0.000 claims description 2
- QPHMWAQUXIDDPS-MBYSJIBESA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CC2=CC=CC=C12)NC)C)=O)=O QPHMWAQUXIDDPS-MBYSJIBESA-N 0.000 claims description 2
- PBWMTPNJEUCDEA-OWZOALSMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-(methylamino)cycloheptyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CCCCC1)NC)C)=O)=O PBWMTPNJEUCDEA-OWZOALSMSA-N 0.000 claims description 2
- OKCAIIWEMWQKMS-YNPPLXCJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CCCC1)NC)C)=O)=O OKCAIIWEMWQKMS-YNPPLXCJSA-N 0.000 claims description 2
- OVUUENFQYGSZAZ-YGFGXBMJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-(methylamino)cyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CCC1)NC)C)=O)=O OVUUENFQYGSZAZ-YGFGXBMJSA-N 0.000 claims description 2
- VVWDFDDESASJGN-PWCSWUJKSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-[[1-(trifluoromethyl)cyclopropyl]methylamino]cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CCCC1)NCC1(CC1)C(F)(F)F)C)=O)=O VVWDFDDESASJGN-PWCSWUJKSA-N 0.000 claims description 2
- JAYWKANBWUUEPJ-LEAGNCFPSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2R)-2-piperidin-1-ylcyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@@H](CCC1)N1CCCCC1)C)=O)=O JAYWKANBWUUEPJ-LEAGNCFPSA-N 0.000 claims description 2
- VDKPJIVXZTYGFX-IZOREMLJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](C2=CC=CC=C2C1)NC)C)=O)=O VDKPJIVXZTYGFX-IZOREMLJSA-N 0.000 claims description 2
- QPHMWAQUXIDDPS-OWJBEEKMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CC2=CC=CC=C12)NC)C)=O)=O QPHMWAQUXIDDPS-OWJBEEKMSA-N 0.000 claims description 2
- PBWMTPNJEUCDEA-MYFVLZFPSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-(methylamino)cycloheptyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CCCCC1)NC)C)=O)=O PBWMTPNJEUCDEA-MYFVLZFPSA-N 0.000 claims description 2
- OKCAIIWEMWQKMS-RTKIROINSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CCCC1)NC)C)=O)=O OKCAIIWEMWQKMS-RTKIROINSA-N 0.000 claims description 2
- OVUUENFQYGSZAZ-QMRHZFGWSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-(methylamino)cyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CCC1)NC)C)=O)=O OVUUENFQYGSZAZ-QMRHZFGWSA-N 0.000 claims description 2
- JAYWKANBWUUEPJ-LFPSWIHMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-piperidin-1-ylcyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CCC1)N1CCCCC1)C)=O)=O JAYWKANBWUUEPJ-LFPSWIHMSA-N 0.000 claims description 2
- VDKPJIVXZTYGFX-FQRLBTLJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](C2=CC=CC=C2C1)NC)C)=O)=O VDKPJIVXZTYGFX-FQRLBTLJSA-N 0.000 claims description 2
- QPHMWAQUXIDDPS-DRPMKMPGSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CC2=CC=CC=C12)NC)C)=O)=O QPHMWAQUXIDDPS-DRPMKMPGSA-N 0.000 claims description 2
- PBWMTPNJEUCDEA-DVKDBIPTSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-(methylamino)cycloheptyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CCCCC1)NC)C)=O)=O PBWMTPNJEUCDEA-DVKDBIPTSA-N 0.000 claims description 2
- OKCAIIWEMWQKMS-GARXDOFDSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CCCC1)NC)C)=O)=O OKCAIIWEMWQKMS-GARXDOFDSA-N 0.000 claims description 2
- OVUUENFQYGSZAZ-YSPPHNQVSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-(methylamino)cyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CCC1)NC)C)=O)=O OVUUENFQYGSZAZ-YSPPHNQVSA-N 0.000 claims description 2
- VVWDFDDESASJGN-YTYFACEESA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-[[1-(trifluoromethyl)cyclopropyl]methylamino]cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CCCC1)NCC1(CC1)C(F)(F)F)C)=O)=O VVWDFDDESASJGN-YTYFACEESA-N 0.000 claims description 2
- JAYWKANBWUUEPJ-ABZYKWASSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2R)-2-piperidin-1-ylcyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@@H](CCC1)N1CCCCC1)C)=O)=O JAYWKANBWUUEPJ-ABZYKWASSA-N 0.000 claims description 2
- VDKPJIVXZTYGFX-ZDZADGERSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-1-(methylamino)-2,3-dihydro-1H-inden-2-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](C2=CC=CC=C2C1)NC)C)=O)=O VDKPJIVXZTYGFX-ZDZADGERSA-N 0.000 claims description 2
- QPHMWAQUXIDDPS-GCSLORGYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-(methylamino)-2,3-dihydro-1H-inden-1-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CC2=CC=CC=C12)NC)C)=O)=O QPHMWAQUXIDDPS-GCSLORGYSA-N 0.000 claims description 2
- PBWMTPNJEUCDEA-UBFHEZILSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-(methylamino)cycloheptyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CCCCC1)NC)C)=O)=O PBWMTPNJEUCDEA-UBFHEZILSA-N 0.000 claims description 2
- OKCAIIWEMWQKMS-PYNWJHIZSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CCCC1)NC)C)=O)=O OKCAIIWEMWQKMS-PYNWJHIZSA-N 0.000 claims description 2
- VVWDFDDESASJGN-ADUPEVMXSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-[[1-(trifluoromethyl)cyclopropyl]methylamino]cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CCCC1)NCC1(CC1)C(F)(F)F)C)=O)=O VVWDFDDESASJGN-ADUPEVMXSA-N 0.000 claims description 2
- JAYWKANBWUUEPJ-NFBCFJMWSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1S,2S)-2-piperidin-1-ylcyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@@H]1[C@H](CCC1)N1CCCCC1)C)=O)=O JAYWKANBWUUEPJ-NFBCFJMWSA-N 0.000 claims description 2
- PBWMTPNJEUCDEA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[2-(methylamino)cycloheptyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1C(CCCCC1)NC)C)=O)=O PBWMTPNJEUCDEA-UHFFFAOYSA-N 0.000 claims description 2
- OKCAIIWEMWQKMS-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1C(CCCC1)NC)C)=O)=O OKCAIIWEMWQKMS-UHFFFAOYSA-N 0.000 claims description 2
- OVUUENFQYGSZAZ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[2-(methylamino)cyclopentyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1C(CCC1)NC)C)=O)=O OVUUENFQYGSZAZ-UHFFFAOYSA-N 0.000 claims description 2
- KRYRZBKHXONMLM-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[2-(pyridin-3-ylmethylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1C(CCCC1)NCC=1C=NC=CC=1)C)=O)=O KRYRZBKHXONMLM-UHFFFAOYSA-N 0.000 claims description 2
- DOOXHGVFAQUURQ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[6-(methylamino)cyclohex-3-en-1-yl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N(C1CC=CCC1NC)C)=O)=O DOOXHGVFAQUURQ-UHFFFAOYSA-N 0.000 claims description 2
- JLNJGGLYXBBCTQ-YGFGXBMJSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-[methyl-[(1R,2R)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N([C@H]1[C@@H](CCCC1)NC)C)=O)=O JLNJGGLYXBBCTQ-YGFGXBMJSA-N 0.000 claims description 2
- JLNJGGLYXBBCTQ-QMRHZFGWSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-[methyl-[(1R,2S)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N([C@H]1[C@H](CCCC1)NC)C)=O)=O JLNJGGLYXBBCTQ-QMRHZFGWSA-N 0.000 claims description 2
- JLNJGGLYXBBCTQ-YSPPHNQVSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-[methyl-[(1S,2R)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N([C@@H]1[C@@H](CCCC1)NC)C)=O)=O JLNJGGLYXBBCTQ-YSPPHNQVSA-N 0.000 claims description 2
- JLNJGGLYXBBCTQ-KSCSMHSMSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-[methyl-[(1S,2S)-2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N([C@@H]1[C@H](CCCC1)NC)C)=O)=O JLNJGGLYXBBCTQ-KSCSMHSMSA-N 0.000 claims description 2
- JLNJGGLYXBBCTQ-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoro-6-[methyl-[2-(methylamino)cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC(=C(C=C2C1=O)F)N(C1C(CCCC1)NC)C)=O)=O JLNJGGLYXBBCTQ-UHFFFAOYSA-N 0.000 claims description 2
- UNJDFSWZCWXKDS-UHFFFAOYSA-N 3-[3-oxo-6-[(2-phenylmethoxycyclohexyl)amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)OC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UNJDFSWZCWXKDS-UHFFFAOYSA-N 0.000 claims description 2
- UIDSGVSTCNIPOM-UHFFFAOYSA-N 3-[3-oxo-6-[(2-piperidin-1-ylcyclopentyl)amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)NC1C(CCC1)N1CCCCC1)C1C(NC(CC1)=O)=O UIDSGVSTCNIPOM-UHFFFAOYSA-N 0.000 claims description 2
- JVLRSIROKDWEFR-PWCSWUJKSA-N 3-[3-oxo-6-[[(1R,2R)-2-(propan-2-ylamino)cyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)(C)N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JVLRSIROKDWEFR-PWCSWUJKSA-N 0.000 claims description 2
- UNJDFSWZCWXKDS-OJVMETQDSA-N 3-[3-oxo-6-[[(1R,2R)-2-phenylmethoxycyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UNJDFSWZCWXKDS-OJVMETQDSA-N 0.000 claims description 2
- UIDSGVSTCNIPOM-LEAGNCFPSA-N 3-[3-oxo-6-[[(1R,2R)-2-piperidin-1-ylcyclopentyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)N[C@H]1[C@@H](CCC1)N1CCCCC1)C1C(NC(CC1)=O)=O UIDSGVSTCNIPOM-LEAGNCFPSA-N 0.000 claims description 2
- JVLRSIROKDWEFR-PAMZHZACSA-N 3-[3-oxo-6-[[(1R,2S)-2-(propan-2-ylamino)cyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)(C)N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JVLRSIROKDWEFR-PAMZHZACSA-N 0.000 claims description 2
- UNJDFSWZCWXKDS-CTDXOEGXSA-N 3-[3-oxo-6-[[(1R,2S)-2-phenylmethoxycyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UNJDFSWZCWXKDS-CTDXOEGXSA-N 0.000 claims description 2
- UIDSGVSTCNIPOM-LFPSWIHMSA-N 3-[3-oxo-6-[[(1R,2S)-2-piperidin-1-ylcyclopentyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)N[C@H]1[C@H](CCC1)N1CCCCC1)C1C(NC(CC1)=O)=O UIDSGVSTCNIPOM-LFPSWIHMSA-N 0.000 claims description 2
- JVLRSIROKDWEFR-YTYFACEESA-N 3-[3-oxo-6-[[(1S,2R)-2-(propan-2-ylamino)cyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)(C)N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JVLRSIROKDWEFR-YTYFACEESA-N 0.000 claims description 2
- UNJDFSWZCWXKDS-OCESARCHSA-N 3-[3-oxo-6-[[(1S,2R)-2-phenylmethoxycyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)O[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UNJDFSWZCWXKDS-OCESARCHSA-N 0.000 claims description 2
- UIDSGVSTCNIPOM-ABZYKWASSA-N 3-[3-oxo-6-[[(1S,2R)-2-piperidin-1-ylcyclopentyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)N[C@@H]1[C@@H](CCC1)N1CCCCC1)C1C(NC(CC1)=O)=O UIDSGVSTCNIPOM-ABZYKWASSA-N 0.000 claims description 2
- JVLRSIROKDWEFR-ADUPEVMXSA-N 3-[3-oxo-6-[[(1S,2S)-2-(propan-2-ylamino)cyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)(C)N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JVLRSIROKDWEFR-ADUPEVMXSA-N 0.000 claims description 2
- UNJDFSWZCWXKDS-LIMDNCRJSA-N 3-[3-oxo-6-[[(1S,2S)-2-phenylmethoxycyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)O[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UNJDFSWZCWXKDS-LIMDNCRJSA-N 0.000 claims description 2
- UIDSGVSTCNIPOM-NFBCFJMWSA-N 3-[3-oxo-6-[[(1S,2S)-2-piperidin-1-ylcyclopentyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(CC2=CC(=CC=C12)N[C@@H]1[C@H](CCC1)N1CCCCC1)C1C(NC(CC1)=O)=O UIDSGVSTCNIPOM-NFBCFJMWSA-N 0.000 claims description 2
- JVLRSIROKDWEFR-UHFFFAOYSA-N 3-[3-oxo-6-[[2-(propan-2-ylamino)cyclohexyl]amino]-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)(C)NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JVLRSIROKDWEFR-UHFFFAOYSA-N 0.000 claims description 2
- QPHJDEJGXFBESL-UHFFFAOYSA-N 3-[6-(3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N1(CCNC2CCCCC12)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O QPHJDEJGXFBESL-UHFFFAOYSA-N 0.000 claims description 2
- UHYSPYYBZAYBFA-UHFFFAOYSA-N 3-[6-[(2-aminocyclohexyl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UHYSPYYBZAYBFA-UHFFFAOYSA-N 0.000 claims description 2
- MCCWSWRETCWRFD-UHFFFAOYSA-N 3-[6-[(2-aminocyclopentyl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NC1C(CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MCCWSWRETCWRFD-UHFFFAOYSA-N 0.000 claims description 2
- BLRLCAQMUGCANX-UHFFFAOYSA-N 3-[6-[(2-hydroxycyclohexyl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BLRLCAQMUGCANX-UHFFFAOYSA-N 0.000 claims description 2
- QPHJDEJGXFBESL-OWZOALSMSA-N 3-[6-[(4aR,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N1(CCN[C@@H]2CCCC[C@@H]12)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O QPHJDEJGXFBESL-OWZOALSMSA-N 0.000 claims description 2
- QPHJDEJGXFBESL-DVKDBIPTSA-N 3-[6-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N1(CCN[C@@H]2CCCC[C@H]12)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O QPHJDEJGXFBESL-DVKDBIPTSA-N 0.000 claims description 2
- QPHJDEJGXFBESL-MYFVLZFPSA-N 3-[6-[(4aS,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N1(CCN[C@H]2CCCC[C@@H]12)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O QPHJDEJGXFBESL-MYFVLZFPSA-N 0.000 claims description 2
- QPHJDEJGXFBESL-UBFHEZILSA-N 3-[6-[(4aS,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N1(CCN[C@H]2CCCC[C@H]12)C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O QPHJDEJGXFBESL-UBFHEZILSA-N 0.000 claims description 2
- GSIOCCZKWYBYFD-LEAGNCFPSA-N 3-[6-[[(1R,2R)-2-(2-methylpropylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C(C)C)N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O GSIOCCZKWYBYFD-LEAGNCFPSA-N 0.000 claims description 2
- SWKNMYVOMPNSKL-OSBQEZSISA-N 3-[6-[[(1R,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O SWKNMYVOMPNSKL-OSBQEZSISA-N 0.000 claims description 2
- HOPXHPVNNTZZOH-WELAQSEPSA-N 3-[6-[[(1R,2R)-2-(benzylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O HOPXHPVNNTZZOH-WELAQSEPSA-N 0.000 claims description 2
- OCJMRBGAANJKCG-WELAQSEPSA-N 3-[6-[[(1R,2R)-2-(cyclohexylmethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)CN[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O OCJMRBGAANJKCG-WELAQSEPSA-N 0.000 claims description 2
- DDATULQPTHGNEF-OWZOALSMSA-N 3-[6-[[(1R,2R)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DDATULQPTHGNEF-OWZOALSMSA-N 0.000 claims description 2
- JFLFBXRKNWTJIB-YNPPLXCJSA-N 3-[6-[[(1R,2R)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@H]1[C@@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JFLFBXRKNWTJIB-YNPPLXCJSA-N 0.000 claims description 2
- KLUWBEKKRGYFKC-OSBQEZSISA-N 3-[6-[[(1R,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F KLUWBEKKRGYFKC-OSBQEZSISA-N 0.000 claims description 2
- CDSAXYIWGJMEPV-AEAWWFNXSA-N 3-[6-[[(1R,2R)-2-[benzyl(methyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N([C@H]1[C@@H](CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)C CDSAXYIWGJMEPV-AEAWWFNXSA-N 0.000 claims description 2
- UHYSPYYBZAYBFA-YGFGXBMJSA-N 3-[6-[[(1R,2R)-2-aminocyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UHYSPYYBZAYBFA-YGFGXBMJSA-N 0.000 claims description 2
- MCCWSWRETCWRFD-GRKKQISMSA-N 3-[6-[[(1R,2R)-2-aminocyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@H]1[C@@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MCCWSWRETCWRFD-GRKKQISMSA-N 0.000 claims description 2
- BLRLCAQMUGCANX-YTPLPTRZSA-N 3-[6-[[(1R,2R)-2-hydroxycyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BLRLCAQMUGCANX-YTPLPTRZSA-N 0.000 claims description 2
- GSIOCCZKWYBYFD-ABZYKWASSA-N 3-[6-[[(1R,2S)-2-(2-methylpropylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C(C)C)N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O GSIOCCZKWYBYFD-ABZYKWASSA-N 0.000 claims description 2
- SWKNMYVOMPNSKL-PDYHCXRVSA-N 3-[6-[[(1R,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O SWKNMYVOMPNSKL-PDYHCXRVSA-N 0.000 claims description 2
- HOPXHPVNNTZZOH-ZVTBYLAHSA-N 3-[6-[[(1R,2S)-2-(benzylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O HOPXHPVNNTZZOH-ZVTBYLAHSA-N 0.000 claims description 2
- OCJMRBGAANJKCG-ZVTBYLAHSA-N 3-[6-[[(1R,2S)-2-(cyclohexylmethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)CN[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O OCJMRBGAANJKCG-ZVTBYLAHSA-N 0.000 claims description 2
- DDATULQPTHGNEF-MYFVLZFPSA-N 3-[6-[[(1R,2S)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DDATULQPTHGNEF-MYFVLZFPSA-N 0.000 claims description 2
- JFLFBXRKNWTJIB-RTKIROINSA-N 3-[6-[[(1R,2S)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@@H]1[C@@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JFLFBXRKNWTJIB-RTKIROINSA-N 0.000 claims description 2
- BSLGNKPENQLGPF-RTKIROINSA-N 3-[6-[[(1R,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BSLGNKPENQLGPF-RTKIROINSA-N 0.000 claims description 2
- KLUWBEKKRGYFKC-MCOCGALXSA-N 3-[6-[[(1R,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F KLUWBEKKRGYFKC-MCOCGALXSA-N 0.000 claims description 2
- CDSAXYIWGJMEPV-ZXABPTRBSA-N 3-[6-[[(1R,2S)-2-[benzyl(methyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N([C@@H]1[C@@H](CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)C CDSAXYIWGJMEPV-ZXABPTRBSA-N 0.000 claims description 2
- UHYSPYYBZAYBFA-QMRHZFGWSA-N 3-[6-[[(1R,2S)-2-aminocyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UHYSPYYBZAYBFA-QMRHZFGWSA-N 0.000 claims description 2
- MCCWSWRETCWRFD-SNTRVMSOSA-N 3-[6-[[(1R,2S)-2-aminocyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@@H]1[C@@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MCCWSWRETCWRFD-SNTRVMSOSA-N 0.000 claims description 2
- BLRLCAQMUGCANX-TUOGLVOQSA-N 3-[6-[[(1R,2S)-2-hydroxycyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O[C@@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BLRLCAQMUGCANX-TUOGLVOQSA-N 0.000 claims description 2
- GSIOCCZKWYBYFD-LFPSWIHMSA-N 3-[6-[[(1S,2R)-2-(2-methylpropylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C(C)C)N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O GSIOCCZKWYBYFD-LFPSWIHMSA-N 0.000 claims description 2
- SWKNMYVOMPNSKL-MCOCGALXSA-N 3-[6-[[(1S,2R)-2-(3-ethoxyazetidin-1-yl)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O SWKNMYVOMPNSKL-MCOCGALXSA-N 0.000 claims description 2
- HOPXHPVNNTZZOH-AXWGZAFASA-N 3-[6-[[(1S,2R)-2-(benzylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O HOPXHPVNNTZZOH-AXWGZAFASA-N 0.000 claims description 2
- OCJMRBGAANJKCG-AXWGZAFASA-N 3-[6-[[(1S,2R)-2-(cyclohexylmethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)CN[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O OCJMRBGAANJKCG-AXWGZAFASA-N 0.000 claims description 2
- DDATULQPTHGNEF-DVKDBIPTSA-N 3-[6-[[(1S,2R)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DDATULQPTHGNEF-DVKDBIPTSA-N 0.000 claims description 2
- JFLFBXRKNWTJIB-GARXDOFDSA-N 3-[6-[[(1S,2R)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@H]1[C@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JFLFBXRKNWTJIB-GARXDOFDSA-N 0.000 claims description 2
- BSLGNKPENQLGPF-GARXDOFDSA-N 3-[6-[[(1S,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BSLGNKPENQLGPF-GARXDOFDSA-N 0.000 claims description 2
- KLUWBEKKRGYFKC-PDYHCXRVSA-N 3-[6-[[(1S,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F KLUWBEKKRGYFKC-PDYHCXRVSA-N 0.000 claims description 2
- CDSAXYIWGJMEPV-CSIQULDISA-N 3-[6-[[(1S,2R)-2-[benzyl(methyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N([C@H]1[C@H](CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)C CDSAXYIWGJMEPV-CSIQULDISA-N 0.000 claims description 2
- UHYSPYYBZAYBFA-YSPPHNQVSA-N 3-[6-[[(1S,2R)-2-aminocyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UHYSPYYBZAYBFA-YSPPHNQVSA-N 0.000 claims description 2
- MCCWSWRETCWRFD-GNXJLENFSA-N 3-[6-[[(1S,2R)-2-aminocyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@H]1[C@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MCCWSWRETCWRFD-GNXJLENFSA-N 0.000 claims description 2
- BLRLCAQMUGCANX-DLDKDUQYSA-N 3-[6-[[(1S,2R)-2-hydroxycyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O[C@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BLRLCAQMUGCANX-DLDKDUQYSA-N 0.000 claims description 2
- GSIOCCZKWYBYFD-NFBCFJMWSA-N 3-[6-[[(1S,2S)-2-(2-methylpropylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C(C)C)N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O GSIOCCZKWYBYFD-NFBCFJMWSA-N 0.000 claims description 2
- SWKNMYVOMPNSKL-AHTKWCMKSA-N 3-[6-[[(1S,2S)-2-(3-ethoxyazetidin-1-yl)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O SWKNMYVOMPNSKL-AHTKWCMKSA-N 0.000 claims description 2
- HOPXHPVNNTZZOH-OJSMNCEXSA-N 3-[6-[[(1S,2S)-2-(benzylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O HOPXHPVNNTZZOH-OJSMNCEXSA-N 0.000 claims description 2
- DDATULQPTHGNEF-UBFHEZILSA-N 3-[6-[[(1S,2S)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DDATULQPTHGNEF-UBFHEZILSA-N 0.000 claims description 2
- JFLFBXRKNWTJIB-PYNWJHIZSA-N 3-[6-[[(1S,2S)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N[C@@H]1[C@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JFLFBXRKNWTJIB-PYNWJHIZSA-N 0.000 claims description 2
- BSLGNKPENQLGPF-PYNWJHIZSA-N 3-[6-[[(1S,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BSLGNKPENQLGPF-PYNWJHIZSA-N 0.000 claims description 2
- KLUWBEKKRGYFKC-AHTKWCMKSA-N 3-[6-[[(1S,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F KLUWBEKKRGYFKC-AHTKWCMKSA-N 0.000 claims description 2
- CDSAXYIWGJMEPV-JWDFLIAJSA-N 3-[6-[[(1S,2S)-2-[benzyl(methyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N([C@@H]1[C@H](CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)C CDSAXYIWGJMEPV-JWDFLIAJSA-N 0.000 claims description 2
- SZZOMYGRNZVWRK-NTZARQNWSA-N 3-[6-[[(1S,2S)-2-[benzyl(methyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N([C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C SZZOMYGRNZVWRK-NTZARQNWSA-N 0.000 claims description 2
- UHYSPYYBZAYBFA-KSCSMHSMSA-N 3-[6-[[(1S,2S)-2-aminocyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O UHYSPYYBZAYBFA-KSCSMHSMSA-N 0.000 claims description 2
- MCCWSWRETCWRFD-ZYOSVBKOSA-N 3-[6-[[(1S,2S)-2-aminocyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound N[C@@H]1[C@H](CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O MCCWSWRETCWRFD-ZYOSVBKOSA-N 0.000 claims description 2
- BLRLCAQMUGCANX-AQOJYXMDSA-N 3-[6-[[(1S,2S)-2-hydroxycyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound O[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BLRLCAQMUGCANX-AQOJYXMDSA-N 0.000 claims description 2
- GSIOCCZKWYBYFD-UHFFFAOYSA-N 3-[6-[[2-(2-methylpropylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C(C)C)NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O GSIOCCZKWYBYFD-UHFFFAOYSA-N 0.000 claims description 2
- CLPXHEIURHOHTH-UHFFFAOYSA-N 3-[6-[[2-(3-ethoxyazetidin-1-yl)cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)C1C(CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C CLPXHEIURHOHTH-UHFFFAOYSA-N 0.000 claims description 2
- SWKNMYVOMPNSKL-UHFFFAOYSA-N 3-[6-[[2-(3-ethoxyazetidin-1-yl)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)OC1CN(C1)C1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O SWKNMYVOMPNSKL-UHFFFAOYSA-N 0.000 claims description 2
- HOPXHPVNNTZZOH-UHFFFAOYSA-N 3-[6-[[2-(benzylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O HOPXHPVNNTZZOH-UHFFFAOYSA-N 0.000 claims description 2
- OCJMRBGAANJKCG-UHFFFAOYSA-N 3-[6-[[2-(cyclohexylmethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)CNC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O OCJMRBGAANJKCG-UHFFFAOYSA-N 0.000 claims description 2
- JFLFBXRKNWTJIB-UHFFFAOYSA-N 3-[6-[[2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)NC1C(CCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O JFLFBXRKNWTJIB-UHFFFAOYSA-N 0.000 claims description 2
- BSLGNKPENQLGPF-UHFFFAOYSA-N 3-[6-[[2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CNC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BSLGNKPENQLGPF-UHFFFAOYSA-N 0.000 claims description 2
- GIHVXFKEPRATCH-UHFFFAOYSA-N 3-[6-[[2-[(3,3-difluorocyclobutyl)methylamino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CC(C1)CNC1C(CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)F GIHVXFKEPRATCH-UHFFFAOYSA-N 0.000 claims description 2
- YATBGXLDABNHLV-UHFFFAOYSA-N 3-[6-[[2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)NC1C(CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)F YATBGXLDABNHLV-UHFFFAOYSA-N 0.000 claims description 2
- KLUWBEKKRGYFKC-UHFFFAOYSA-N 3-[6-[[2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)F KLUWBEKKRGYFKC-UHFFFAOYSA-N 0.000 claims description 2
- CDSAXYIWGJMEPV-UHFFFAOYSA-N 3-[6-[[2-[benzyl(methyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C1=CC=CC=C1)N(C1C(CCCC1)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C)C CDSAXYIWGJMEPV-UHFFFAOYSA-N 0.000 claims description 2
- NXPINYXVXVKKSQ-ABZYKWASSA-N 3-[6-[ethyl-[(1R,2S)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@H](CCCC1)NCC NXPINYXVXVKKSQ-ABZYKWASSA-N 0.000 claims description 2
- NXPINYXVXVKKSQ-LFPSWIHMSA-N 3-[6-[ethyl-[(1S,2R)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@@H](CCCC1)NCC NXPINYXVXVKKSQ-LFPSWIHMSA-N 0.000 claims description 2
- NXPINYXVXVKKSQ-NFBCFJMWSA-N 3-[6-[ethyl-[(1S,2S)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@H](CCCC1)NCC NXPINYXVXVKKSQ-NFBCFJMWSA-N 0.000 claims description 2
- AFSRZAIZWYMZAB-ADUPEVMXSA-N 3-[6-[ethyl-[(1S,2S)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@H](CCC1)NCC AFSRZAIZWYMZAB-ADUPEVMXSA-N 0.000 claims description 2
- NXPINYXVXVKKSQ-UHFFFAOYSA-N 3-[6-[ethyl-[2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1C(CCCC1)NCC NXPINYXVXVKKSQ-UHFFFAOYSA-N 0.000 claims description 2
- AFSRZAIZWYMZAB-UHFFFAOYSA-N 3-[6-[ethyl-[2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1C(CCC1)NCC AFSRZAIZWYMZAB-UHFFFAOYSA-N 0.000 claims description 2
- XOFITFABTKWMAL-UHFFFAOYSA-N 3-[6-[methyl-(2-piperidin-1-ylcyclopentyl)amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1C(CCC1)N1CCCCC1 XOFITFABTKWMAL-UHFFFAOYSA-N 0.000 claims description 2
- KGTMEUQVYCUNGD-YNPPLXCJSA-N 3-[6-[methyl-[(1R,2R)-2-(methylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@@H](CCC1)NC KGTMEUQVYCUNGD-YNPPLXCJSA-N 0.000 claims description 2
- XOFITFABTKWMAL-OSBQEZSISA-N 3-[6-[methyl-[(1R,2R)-2-piperidin-1-ylcyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@@H](CCC1)N1CCCCC1 XOFITFABTKWMAL-OSBQEZSISA-N 0.000 claims description 2
- PRGCLFLBCUVASG-MYFVLZFPSA-N 3-[6-[methyl-[(1R,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@H](CCCC1)NC PRGCLFLBCUVASG-MYFVLZFPSA-N 0.000 claims description 2
- KGTMEUQVYCUNGD-RTKIROINSA-N 3-[6-[methyl-[(1R,2S)-2-(methylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@H](CCC1)NC KGTMEUQVYCUNGD-RTKIROINSA-N 0.000 claims description 2
- XOFITFABTKWMAL-PDYHCXRVSA-N 3-[6-[methyl-[(1R,2S)-2-piperidin-1-ylcyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@H](CCC1)N1CCCCC1 XOFITFABTKWMAL-PDYHCXRVSA-N 0.000 claims description 2
- PRGCLFLBCUVASG-DVKDBIPTSA-N 3-[6-[methyl-[(1S,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@@H](CCCC1)NC PRGCLFLBCUVASG-DVKDBIPTSA-N 0.000 claims description 2
- KGTMEUQVYCUNGD-GARXDOFDSA-N 3-[6-[methyl-[(1S,2R)-2-(methylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@@H](CCC1)NC KGTMEUQVYCUNGD-GARXDOFDSA-N 0.000 claims description 2
- PRGCLFLBCUVASG-UBFHEZILSA-N 3-[6-[methyl-[(1S,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@H](CCCC1)NC PRGCLFLBCUVASG-UBFHEZILSA-N 0.000 claims description 2
- KGTMEUQVYCUNGD-PYNWJHIZSA-N 3-[6-[methyl-[(1S,2S)-2-(methylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@H](CCC1)NC KGTMEUQVYCUNGD-PYNWJHIZSA-N 0.000 claims description 2
- XOFITFABTKWMAL-AHTKWCMKSA-N 3-[6-[methyl-[(1S,2S)-2-piperidin-1-ylcyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@H](CCC1)N1CCCCC1 XOFITFABTKWMAL-AHTKWCMKSA-N 0.000 claims description 2
- PRGCLFLBCUVASG-UHFFFAOYSA-N 3-[6-[methyl-[2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1C(CCCC1)NC PRGCLFLBCUVASG-UHFFFAOYSA-N 0.000 claims description 2
- KGTMEUQVYCUNGD-UHFFFAOYSA-N 3-[6-[methyl-[2-(methylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1C(CCC1)NC KGTMEUQVYCUNGD-UHFFFAOYSA-N 0.000 claims description 2
- ILGGZQNITKUTHD-UHFFFAOYSA-N 3-[6-[methyl-[6-(methylamino)cyclohex-3-en-1-yl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)C1CC=CCC1NC ILGGZQNITKUTHD-UHFFFAOYSA-N 0.000 claims description 2
- VUWWSCQZBQJPMF-UHFFFAOYSA-N 3-[7-amino-6-[[2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound NC1=C2CN(C(C2=CC=C1N(C)C1C(CCCC1)NC1CCC(CC1)(F)F)=O)C1C(NC(CC1)=O)=O VUWWSCQZBQJPMF-UHFFFAOYSA-N 0.000 claims description 2
- FLQNJRCBMUFCHN-BLBXNVQISA-N 3-[7-fluoro-6-[methyl-[(1R,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1=C2CN(C(C2=CC=C1N([C@H]1[C@@H](CCCC1)NC)C)=O)C1C(NC(CC1)=O)=O FLQNJRCBMUFCHN-BLBXNVQISA-N 0.000 claims description 2
- FLQNJRCBMUFCHN-BTPDTDQASA-N 3-[7-fluoro-6-[methyl-[(1R,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1=C2CN(C(C2=CC=C1N([C@H]1[C@H](CCCC1)NC)C)=O)C1C(NC(CC1)=O)=O FLQNJRCBMUFCHN-BTPDTDQASA-N 0.000 claims description 2
- FLQNJRCBMUFCHN-CKDQBVIESA-N 3-[7-fluoro-6-[methyl-[(1S,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1=C2CN(C(C2=CC=C1N([C@@H]1[C@@H](CCCC1)NC)C)=O)C1C(NC(CC1)=O)=O FLQNJRCBMUFCHN-CKDQBVIESA-N 0.000 claims description 2
- FLQNJRCBMUFCHN-GIIGEWEBSA-N 3-[7-fluoro-6-[methyl-[(1S,2S)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1=C2CN(C(C2=CC=C1N([C@@H]1[C@H](CCCC1)NC)C)=O)C1C(NC(CC1)=O)=O FLQNJRCBMUFCHN-GIIGEWEBSA-N 0.000 claims description 2
- FLQNJRCBMUFCHN-UHFFFAOYSA-N 3-[7-fluoro-6-[methyl-[2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1=C2CN(C(C2=CC=C1N(C1C(CCCC1)NC)C)=O)C1C(NC(CC1)=O)=O FLQNJRCBMUFCHN-UHFFFAOYSA-N 0.000 claims description 2
- LCUORYPDBGHMPS-QNZPCDNOSA-N 4-amino-5-[[(1R,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1N(C)[C@H]1[C@@H](CCCC1)NC1CCC(CC1)(F)F)=O)C1C(NC(CC1)=O)=O)=O LCUORYPDBGHMPS-QNZPCDNOSA-N 0.000 claims description 2
- LCUORYPDBGHMPS-FQZXCLDYSA-N 4-amino-5-[[(1S,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1N(C)[C@@H]1[C@@H](CCCC1)NC1CCC(CC1)(F)F)=O)C1C(NC(CC1)=O)=O)=O LCUORYPDBGHMPS-FQZXCLDYSA-N 0.000 claims description 2
- LCUORYPDBGHMPS-YGYNJSFOSA-N 4-amino-5-[[(1S,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1N(C)[C@@H]1[C@H](CCCC1)NC1CCC(CC1)(F)F)=O)C1C(NC(CC1)=O)=O)=O LCUORYPDBGHMPS-YGYNJSFOSA-N 0.000 claims description 2
- KCTPGBMIBNLUOQ-YNPPLXCJSA-N 5-[(4aR,8aR)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoxalin-1-yl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N1CCN[C@@H]2CCCC[C@@H]12)=O)=O KCTPGBMIBNLUOQ-YNPPLXCJSA-N 0.000 claims description 2
- NJHYKEANORSRJK-WELAQSEPSA-N 5-[[(1R,2R)-2-(benzylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C1=CC=CC=C1)N[C@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C NJHYKEANORSRJK-WELAQSEPSA-N 0.000 claims description 2
- CNVIJJQAFZJUCM-PWCSWUJKSA-N 5-[[(1R,2R)-2-(diethylamino)cyclopentyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C)N([C@H]1[C@@H](CCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)CC CNVIJJQAFZJUCM-PWCSWUJKSA-N 0.000 claims description 2
- GRSMUWASIAPNRH-OWZOALSMSA-N 5-[[(1R,2R)-2-(dimethylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)C GRSMUWASIAPNRH-OWZOALSMSA-N 0.000 claims description 2
- IOSBUGPPJHKPFA-YNPPLXCJSA-N 5-[[(1R,2R)-2-(dimethylamino)cyclohexyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@H]1[C@@H](CCCC1)NC=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C IOSBUGPPJHKPFA-YNPPLXCJSA-N 0.000 claims description 2
- VBCZSAGJAGMPTR-LEAGNCFPSA-N 5-[[(1R,2R)-2-[(3,3-difluorocyclobutyl)methylamino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound FC1(CC(C1)CN[C@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)F VBCZSAGJAGMPTR-LEAGNCFPSA-N 0.000 claims description 2
- KLULSGAARMYBSZ-QNZPCDNOSA-N 5-[[(1R,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione Chemical compound FC1(CCC(CC1)N[C@H]1[C@@H](CCCC1)N(C=1C(=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)O)C)F KLULSGAARMYBSZ-QNZPCDNOSA-N 0.000 claims description 2
- UNCMECUBEPXFGV-YGFGXBMJSA-N 5-[[(1R,2R)-2-aminocyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound N[C@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C UNCMECUBEPXFGV-YGFGXBMJSA-N 0.000 claims description 2
- NJHYKEANORSRJK-ZVTBYLAHSA-N 5-[[(1R,2S)-2-(benzylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C1=CC=CC=C1)N[C@@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C NJHYKEANORSRJK-ZVTBYLAHSA-N 0.000 claims description 2
- CNVIJJQAFZJUCM-YTYFACEESA-N 5-[[(1R,2S)-2-(diethylamino)cyclopentyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C)N([C@@H]1[C@@H](CCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)CC CNVIJJQAFZJUCM-YTYFACEESA-N 0.000 claims description 2
- GRSMUWASIAPNRH-MYFVLZFPSA-N 5-[[(1R,2S)-2-(dimethylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)C GRSMUWASIAPNRH-MYFVLZFPSA-N 0.000 claims description 2
- IOSBUGPPJHKPFA-GARXDOFDSA-N 5-[[(1R,2S)-2-(dimethylamino)cyclohexyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@@H]1[C@@H](CCCC1)NC=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C IOSBUGPPJHKPFA-GARXDOFDSA-N 0.000 claims description 2
- VBCZSAGJAGMPTR-ABZYKWASSA-N 5-[[(1R,2S)-2-[(3,3-difluorocyclobutyl)methylamino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound FC1(CC(C1)CN[C@@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)F VBCZSAGJAGMPTR-ABZYKWASSA-N 0.000 claims description 2
- KLULSGAARMYBSZ-PZEDNMLSSA-N 5-[[(1R,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione Chemical compound FC1(CCC(CC1)N[C@@H]1[C@@H](CCCC1)N(C=1C(=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)O)C)F KLULSGAARMYBSZ-PZEDNMLSSA-N 0.000 claims description 2
- UNCMECUBEPXFGV-QMRHZFGWSA-N 5-[[(1R,2S)-2-aminocyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound N[C@@H]1[C@@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C UNCMECUBEPXFGV-QMRHZFGWSA-N 0.000 claims description 2
- NJHYKEANORSRJK-AXWGZAFASA-N 5-[[(1S,2R)-2-(benzylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C1=CC=CC=C1)N[C@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C NJHYKEANORSRJK-AXWGZAFASA-N 0.000 claims description 2
- CNVIJJQAFZJUCM-PAMZHZACSA-N 5-[[(1S,2R)-2-(diethylamino)cyclopentyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C)N([C@H]1[C@H](CCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)CC CNVIJJQAFZJUCM-PAMZHZACSA-N 0.000 claims description 2
- GRSMUWASIAPNRH-DVKDBIPTSA-N 5-[[(1S,2R)-2-(dimethylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)C GRSMUWASIAPNRH-DVKDBIPTSA-N 0.000 claims description 2
- IOSBUGPPJHKPFA-RTKIROINSA-N 5-[[(1S,2R)-2-(dimethylamino)cyclohexyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@H]1[C@H](CCCC1)NC=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C IOSBUGPPJHKPFA-RTKIROINSA-N 0.000 claims description 2
- VBCZSAGJAGMPTR-LFPSWIHMSA-N 5-[[(1S,2R)-2-[(3,3-difluorocyclobutyl)methylamino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound FC1(CC(C1)CN[C@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)F VBCZSAGJAGMPTR-LFPSWIHMSA-N 0.000 claims description 2
- KLULSGAARMYBSZ-FQZXCLDYSA-N 5-[[(1S,2R)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione Chemical compound FC1(CCC(CC1)N[C@H]1[C@H](CCCC1)N(C=1C(=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)O)C)F KLULSGAARMYBSZ-FQZXCLDYSA-N 0.000 claims description 2
- UNCMECUBEPXFGV-YSPPHNQVSA-N 5-[[(1S,2R)-2-aminocyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound N[C@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C UNCMECUBEPXFGV-YSPPHNQVSA-N 0.000 claims description 2
- NJHYKEANORSRJK-OJSMNCEXSA-N 5-[[(1S,2S)-2-(benzylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C1=CC=CC=C1)N[C@@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C NJHYKEANORSRJK-OJSMNCEXSA-N 0.000 claims description 2
- CNVIJJQAFZJUCM-ADUPEVMXSA-N 5-[[(1S,2S)-2-(diethylamino)cyclopentyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C)N([C@@H]1[C@H](CCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)CC CNVIJJQAFZJUCM-ADUPEVMXSA-N 0.000 claims description 2
- GRSMUWASIAPNRH-UBFHEZILSA-N 5-[[(1S,2S)-2-(dimethylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN([C@@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)C GRSMUWASIAPNRH-UBFHEZILSA-N 0.000 claims description 2
- VBCZSAGJAGMPTR-NFBCFJMWSA-N 5-[[(1S,2S)-2-[(3,3-difluorocyclobutyl)methylamino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound FC1(CC(C1)CN[C@@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)F VBCZSAGJAGMPTR-NFBCFJMWSA-N 0.000 claims description 2
- KLULSGAARMYBSZ-YGYNJSFOSA-N 5-[[(1S,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindole-1,3-dione Chemical compound FC1(CCC(CC1)N[C@@H]1[C@H](CCCC1)N(C=1C(=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)O)C)F KLULSGAARMYBSZ-YGYNJSFOSA-N 0.000 claims description 2
- UNCMECUBEPXFGV-KSCSMHSMSA-N 5-[[(1S,2S)-2-aminocyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound N[C@@H]1[C@H](CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C UNCMECUBEPXFGV-KSCSMHSMSA-N 0.000 claims description 2
- NJHYKEANORSRJK-UHFFFAOYSA-N 5-[[2-(benzylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C1=CC=CC=C1)NC1C(CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C NJHYKEANORSRJK-UHFFFAOYSA-N 0.000 claims description 2
- CNVIJJQAFZJUCM-UHFFFAOYSA-N 5-[[2-(diethylamino)cyclopentyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound C(C)N(C1C(CCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)CC CNVIJJQAFZJUCM-UHFFFAOYSA-N 0.000 claims description 2
- GRSMUWASIAPNRH-UHFFFAOYSA-N 5-[[2-(dimethylamino)cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN(C1C(CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)C GRSMUWASIAPNRH-UHFFFAOYSA-N 0.000 claims description 2
- IOSBUGPPJHKPFA-UHFFFAOYSA-N 5-[[2-(dimethylamino)cyclohexyl]amino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound CN(C1C(CCCC1)NC=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C IOSBUGPPJHKPFA-UHFFFAOYSA-N 0.000 claims description 2
- OBBMAAXRXVMOFO-UHFFFAOYSA-N 5-[[2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound FC1(CCC(CC1)NC1C(CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C)F OBBMAAXRXVMOFO-UHFFFAOYSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 5
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- VVWDFDDESASJGN-PAMZHZACSA-N 2-(2,6-dioxopiperidin-3-yl)-5-[methyl-[(1R,2S)-2-[[1-(trifluoromethyl)cyclopropyl]methylamino]cyclohexyl]amino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=C(C=C2C1=O)N([C@H]1[C@H](CCCC1)NCC1(CC1)C(F)(F)F)C)=O)=O VVWDFDDESASJGN-PAMZHZACSA-N 0.000 claims 1
- OCJMRBGAANJKCG-OJSMNCEXSA-N 3-[6-[[(1S,2S)-2-(cyclohexylmethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C1(CCCCC1)CN[C@@H]1[C@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O OCJMRBGAANJKCG-OJSMNCEXSA-N 0.000 claims 1
- NXPINYXVXVKKSQ-LEAGNCFPSA-N 3-[6-[ethyl-[(1R,2R)-2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@@H](CCCC1)NCC NXPINYXVXVKKSQ-LEAGNCFPSA-N 0.000 claims 1
- XOFITFABTKWMAL-MCOCGALXSA-N 3-[6-[methyl-[(1S,2R)-2-piperidin-1-ylcyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@@H](CCC1)N1CCCCC1 XOFITFABTKWMAL-MCOCGALXSA-N 0.000 claims 1
- LCUORYPDBGHMPS-PZEDNMLSSA-N 4-amino-5-[[(1R,2S)-2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1=C2C(N(C(C2=CC=C1N(C)[C@H]1[C@H](CCCC1)NC1CCC(CC1)(F)F)=O)C1C(NC(CC1)=O)=O)=O LCUORYPDBGHMPS-PZEDNMLSSA-N 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- BSLGNKPENQLGPF-YNPPLXCJSA-N 3-[6-[[(1R,2R)-2-(methylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound CN[C@H]1[C@@H](CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O BSLGNKPENQLGPF-YNPPLXCJSA-N 0.000 description 1
- DDATULQPTHGNEF-UHFFFAOYSA-N 3-[6-[[2-(ethylamino)cyclohexyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)NC1C(CCCC1)NC=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O DDATULQPTHGNEF-UHFFFAOYSA-N 0.000 description 1
- KMQDHJJTZXRBAF-UHFFFAOYSA-N 3-[6-[[2-[(4,4-difluorocyclohexyl)amino]cyclohexyl]-methylamino]-7-hydroxy-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound FC1(CCC(CC1)NC1C(CCCC1)N(C=1C(=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)O)C)F KMQDHJJTZXRBAF-UHFFFAOYSA-N 0.000 description 1
- AFSRZAIZWYMZAB-PWCSWUJKSA-N 3-[6-[ethyl-[(1R,2R)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@@H](CCC1)NCC AFSRZAIZWYMZAB-PWCSWUJKSA-N 0.000 description 1
- AFSRZAIZWYMZAB-PAMZHZACSA-N 3-[6-[ethyl-[(1R,2S)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@H]1[C@H](CCC1)NCC AFSRZAIZWYMZAB-PAMZHZACSA-N 0.000 description 1
- AFSRZAIZWYMZAB-YTYFACEESA-N 3-[6-[ethyl-[(1S,2R)-2-(ethylamino)cyclopentyl]amino]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound C(C)N(C=1C=C2CN(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)[C@@H]1[C@@H](CCC1)NCC AFSRZAIZWYMZAB-YTYFACEESA-N 0.000 description 1
- UNCMECUBEPXFGV-UHFFFAOYSA-N 5-[(2-aminocyclohexyl)-methylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1C(CCCC1)N(C=1C=C2C(N(C(C2=CC=1)=O)C1C(NC(CC1)=O)=O)=O)C UNCMECUBEPXFGV-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695922P | 2018-07-10 | 2018-07-10 | |
| US62/695,922 | 2018-07-10 | ||
| PCT/IB2019/055807 WO2020012337A1 (en) | 2018-07-10 | 2019-07-08 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529812A JP2021529812A (ja) | 2021-11-04 |
| JPWO2020012337A5 true JPWO2020012337A5 (https=) | 2022-07-13 |
| JP2021529812A5 JP2021529812A5 (https=) | 2022-07-13 |
| JP7462606B2 JP7462606B2 (ja) | 2024-04-05 |
Family
ID=68136442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500409A Active JP7462606B2 (ja) | 2018-07-10 | 2019-07-08 | ３－（５－アミノ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の治療におけるその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11185537B2 (https=) |
| EP (1) | EP3820574B1 (https=) |
| JP (1) | JP7462606B2 (https=) |
| KR (1) | KR20210031923A (https=) |
| CN (1) | CN112334194B (https=) |
| AR (1) | AR116109A1 (https=) |
| AU (1) | AU2019301947B2 (https=) |
| BR (2) | BR112021000049B1 (https=) |
| CA (1) | CA3103674A1 (https=) |
| ES (1) | ES2963695T3 (https=) |
| MX (1) | MX2021000310A (https=) |
| PY (1) | PY1954554A (https=) |
| TW (1) | TWI830747B (https=) |
| UY (1) | UY38296A (https=) |
| WO (1) | WO2020012337A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| WO2020102226A1 (en) * | 2018-11-13 | 2020-05-22 | Nantcell, Inc | Combination therapies for multiple myeloma |
| KR20210106437A (ko) * | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528B (zh) * | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| AU2020387392B2 (en) | 2019-11-19 | 2025-09-11 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of Helios protein |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| CN115916199A (zh) * | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| IL302038A (en) * | 2020-10-14 | 2023-06-01 | C4 Therapeutics Inc | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
| CN116457339A (zh) * | 2020-10-14 | 2023-07-18 | C4医药公司 | 用于医学治疗的降解新底物的三环化合物 |
| CN116669769A (zh) * | 2020-10-16 | 2023-08-29 | 达纳－法伯癌症研究所公司 | Helios的哌啶基小分子降解剂和使用方法 |
| UY39671A (es) * | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| BR112023020077A2 (pt) | 2021-04-06 | 2023-11-14 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituída por piridinila |
| CN117355299A (zh) * | 2021-04-29 | 2024-01-05 | 尼奥莫夫公司 | 取代的2-(2,6-二氧代哌啶-3-基)-5-(1-哌啶-4-基)异吲哚啉-1,3-二酮衍生物及其用途 |
| CA3209633A1 (en) * | 2021-04-29 | 2022-11-03 | Tinghu Zhang | Phthalimido cereblon complex binders and transcription factor degraders and methods of use |
| BR112023025403A2 (pt) | 2021-06-25 | 2024-02-20 | Korea Res Inst Chemical Tech | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
| EP4366835A1 (en) * | 2021-07-09 | 2024-05-15 | Plexium, Inc. | Heterocycloalkyl and heteroaryl compounds and pharmaceutical compositions that modulate ikzf2 |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| WO2023283430A1 (en) * | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Cycloalkyl compounds and pharmaceutical compositions that modulate ikzf2 |
| US20250066325A1 (en) * | 2021-11-04 | 2025-02-27 | The Brigham And Women's Hospital, Inc. | Directed degron molecules and applications thereof |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| CN114853754B (zh) | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | 一种硫代酰胺衍生物及其制备方法和应用 |
Family Cites Families (455)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4433059A (en) | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
| US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5221543A (en) * | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| JPH021556A (ja) | 1988-06-09 | 1990-01-05 | Snow Brand Milk Prod Co Ltd | ハイブリッド抗体及びその作製方法 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US5273743A (en) | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| GB9012995D0 (en) | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| HU215180B (hu) | 1992-01-23 | 1998-10-28 | Merck Patent Gmbh. | Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| AU675223B2 (en) | 1992-05-08 | 1997-01-30 | Creative Biomolecules, Inc. | Chimeric multivalent protein analogues and methods of use thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US7196170B2 (en) | 1992-09-14 | 2007-03-27 | The General Hospital Corporation | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| SG41929A1 (en) | 1992-09-25 | 1997-08-15 | Commw Scient Ind Res Org | Target binding polypeptide |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| GB9323648D0 (en) | 1992-11-23 | 1994-01-05 | Zeneca Ltd | Proteins |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| US5843674A (en) | 1993-11-16 | 1998-12-01 | Pola Chemical Industries Inc. | Anti-human tyrosinase monoclonal antibody |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| AU706443B2 (en) | 1994-04-22 | 1999-06-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Melanoma antigens |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP3659261B2 (ja) | 1994-10-20 | 2005-06-15 | モルフォシス・アクチェンゲゼルシャフト | 組換体タンパク質の多機能性複合体への標的化ヘテロ結合 |
| WO1996022384A1 (en) | 1995-01-18 | 1996-07-25 | Boehringer Mannheim Gmbh | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| DE69726404T2 (de) | 1996-01-05 | 2004-09-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mesothelinantigen, verfahren und testsatz zur targetierung |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| DE69703121D1 (de) | 1996-10-25 | 2000-10-19 | Us Health | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| AU736707B2 (en) | 1997-06-11 | 2001-08-02 | Anaphore, Inc. | Trimerising module |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| ATE317437T1 (de) | 1997-12-01 | 2006-02-15 | Us Gov Health & Human Serv | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| ES2234241T3 (es) | 1998-01-23 | 2005-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Derivados de anticuerpo de multiples fines. |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6803448B1 (en) | 1998-07-22 | 2004-10-12 | Vanderbilt University | GBS toxin receptor |
| EP1100830B1 (en) | 1998-07-28 | 2003-10-01 | Micromet AG | Heterominibodies |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| AU776788C (en) | 1998-12-16 | 2005-10-27 | Warner-Lambert Company | Treatment of arthritis with MEK inhibitors |
| US6528481B1 (en) | 1999-02-16 | 2003-03-04 | The Burnam Institute | NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| UA75049C2 (uk) | 1999-08-17 | 2006-03-15 | Байоджен Айдек Ма Інк. | Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма |
| ATE388167T1 (de) | 1999-09-30 | 2008-03-15 | Kyowa Hakko Kogyo Kk | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 |
| EP1235847B1 (en) | 1999-11-29 | 2016-01-20 | The Trustees of Columbia University in the City of New York | ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| ATE510855T1 (de) | 2000-03-06 | 2011-06-15 | Univ Kentucky Res Found | Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| JP2004523205A (ja) | 2000-07-25 | 2004-08-05 | イムノメディクス， インコーポレイテッド | 多価標的結合タンパク質 |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP2351838A1 (en) | 2000-10-20 | 2011-08-03 | Chugai Seiyaku Kabushiki Kaisha | Crosslinking agonistic antibodies |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| AU2001291195A1 (en) | 2000-12-01 | 2002-06-11 | Parker Hughes Institute | Nucleotide and protein sequence of helios 3 and methods of use |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2002072635A2 (en) | 2001-03-13 | 2002-09-19 | University College London | Specific binding members |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2003014315A2 (en) | 2001-08-06 | 2003-02-20 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| EP1456234B1 (en) | 2001-08-23 | 2014-04-09 | Rsr Limited | Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| EP1470159B1 (en) | 2001-12-04 | 2013-08-07 | Dana-Farber Cancer Institute, Inc. | Antibody to latent membrane proteins and uses thereof |
| US20030211078A1 (en) | 2001-12-07 | 2003-11-13 | Heavner George A. | Pseudo-antibody constructs |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| AU2003224672B2 (en) | 2002-03-08 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| EP1500665B1 (en) | 2002-04-15 | 2011-06-15 | Chugai Seiyaku Kabushiki Kaisha | METHODS FOR CONSTRUCTING scDb LIBRARIES |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| ATE415413T1 (de) | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
| US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| WO2004045532A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| JP4744147B2 (ja) | 2002-11-26 | 2011-08-10 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定 |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB0305702D0 (en) | 2003-03-12 | 2003-04-16 | Univ Birmingham | Bispecific antibodies |
| WO2004087758A2 (en) | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
| US20050003403A1 (en) | 2003-04-22 | 2005-01-06 | Rossi Edmund A. | Polyvalent protein complex |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| CA2530605A1 (en) | 2003-06-27 | 2005-05-26 | Diadexus, Inc. | Pro104 antibody compositions and methods of use |
| KR20060041205A (ko) | 2003-07-01 | 2006-05-11 | 이뮤노메딕스, 인코오포레이티드 | 양특이성 항체들의 다가 담체들 |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| JP2007525971A (ja) | 2003-08-05 | 2007-09-13 | モルフォテック、インク． | 癌に関連する変異体細胞表面分子 |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| JPWO2005035577A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | ガングリオシドｇｄ３に特異的に結合する抗体組成物 |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050136051A1 (en) | 2003-12-22 | 2005-06-23 | Bernard Scallon | Methods for generating multimeric molecules |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| DK2311873T3 (en) | 2004-01-07 | 2018-11-26 | Novartis Vaccines & Diagnostics Inc | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| US8383575B2 (en) | 2004-01-30 | 2013-02-26 | Paul Scherrer Institut | (DI)barnase-barstar complexes |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| WO2005094818A1 (en) | 2004-03-23 | 2005-10-13 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| US20070161696A1 (en) | 2004-04-23 | 2007-07-12 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| KR20120064120A (ko) | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| BRPI0511350A (pt) | 2004-07-02 | 2007-12-04 | Genentech Inc | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| EP1789446A2 (en) | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| BRPI0514865A (pt) | 2004-09-03 | 2008-06-24 | Celgene Corp | processo para preparar um composto |
| WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法 |
| EP2404895A1 (en) | 2004-10-04 | 2012-01-11 | Regents of the University of Minnesota | Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
| BRPI0518793A2 (pt) | 2004-12-01 | 2008-12-09 | Celgene Corp | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica |
| DE602005023646D1 (de) | 2004-12-10 | 2010-10-28 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| US20080247944A1 (en) | 2005-01-12 | 2008-10-09 | Robert Graziano | Irta-2 Antibodies and Their Uses |
| WO2006086469A2 (en) | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP1874824A4 (en) | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| EP1726650A1 (en) | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| KR20080019249A (ko) | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| WO2007004415A1 (ja) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1901091B1 (en) | 2005-07-04 | 2013-08-21 | Nikon Vision Co., Ltd. | Distance measuring apparatus |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| KR20130108481A (ko) | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE452913T1 (de) | 2005-08-26 | 2010-01-15 | Pls Design Gmbh | Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen |
| KR20080042158A (ko) | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| US8383118B2 (en) | 2005-12-08 | 2013-02-26 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
| ZA200804717B (en) | 2005-12-29 | 2010-02-24 | Anthrogenesis Corp | Improved composition for collecting and preserving a placental stem cells and methods of using the composition |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| WO2007095338A2 (en) | 2006-02-15 | 2007-08-23 | Imclone Systems Incorporated | Functional antibodies |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| WO2007109321A2 (en) | 2006-03-20 | 2007-09-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
| US8946391B2 (en) | 2006-03-24 | 2015-02-03 | The Regents Of The University Of California | Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| JP5165672B2 (ja) | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| PE20080359A1 (es) | 2006-04-19 | 2008-06-06 | Novartis Ag | Compuestos de benzoxazol y benzotiazol 6-0-sustituidos y metodos de inhibicion de la senalizacion de csf-1r |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| US20070269827A1 (en) | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
| JP5189082B2 (ja) | 2006-05-25 | 2013-04-24 | バイエル・ファルマ・アクチェンゲゼルシャフト | 二量体分子複合体 |
| US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
| WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| KR101342035B1 (ko) | 2006-06-20 | 2013-12-16 | 한국과학기술연구원 | 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법 |
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| ES2376771T3 (es) | 2006-08-21 | 2012-03-16 | Genentech, Inc. | Compuestos aza-benzofuranilo y métodos de utilización |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| EP2083868A2 (en) | 2006-10-04 | 2009-08-05 | Københavns Universitet | Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies |
| FR2906808B1 (fr) | 2006-10-10 | 2012-10-05 | Univ Nantes | Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers |
| CA2668208C (en) | 2006-11-02 | 2017-09-12 | Daniel J. Capon | Hybrid immunoglobulins with moving parts |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| JP2010519178A (ja) | 2006-11-23 | 2010-06-03 | ノバルティス アーゲー | ピリミジン類およびｃｘｃｒ２受容体アンタゴニストとしてのその使用 |
| CA2669579A1 (en) | 2006-11-23 | 2008-05-29 | Novartis Ag | 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
| DE602007009865D1 (de) | 2006-11-23 | 2010-11-25 | Novartis Ag | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten |
| WO2008101234A2 (en) | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| WO2008103645A2 (en) | 2007-02-19 | 2008-08-28 | Wisconsin Alumni Research Foundation | Prostate cancer and melanoma antigens |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| CA2682093A1 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20130150A1 (es) | 2007-04-30 | 2013-02-27 | Genentech Inc | Inhibidores de las iap |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2009017679A2 (en) | 2007-07-31 | 2009-02-05 | Merck & Co., Inc. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| WO2009021754A2 (en) | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP2009092508A (ja) | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| EP3103814A1 (en) | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| AU2008328726B2 (en) | 2007-11-30 | 2014-06-12 | Glaxo Group Limited | Antigen-binding constructs |
| WO2009068621A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Method for classifying cancer patients as responder or non-responder to immunotherapy |
| AU2008343065B2 (en) | 2007-12-19 | 2012-04-05 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| KR100957051B1 (ko) | 2007-12-28 | 2010-05-13 | 한국과학기술연구원 | 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| GB2456390A (en) | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US20110009429A1 (en) | 2008-02-26 | 2011-01-13 | Paul Oakley | Heterocyclic compounds as inhibitors of cxcr2 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US20090307179A1 (en) | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009293007B2 (en) | 2008-09-19 | 2015-10-08 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| PE20110547A1 (es) | 2008-10-29 | 2011-08-04 | Celgene Corp | Compuestos de isoindolina con actividad anticancerigena |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| HRP20150766T1 (hr) | 2009-03-20 | 2015-08-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oksidirani derivati triazolilpurina, korisni kao ligandi adenozinskog receptora a2a, te namijenjeni upotrebi kao medikamenti |
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| US8492119B2 (en) | 2009-04-27 | 2013-07-23 | Kyowa Hakko Kirin Co., Ltd | Antibody to human IL-3 receptor alpha chain |
| MX2012001504A (es) | 2009-08-05 | 2012-06-01 | Versitech Ltd | Compuestos antivirales y metodos para elaborarlos y usarlos. |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| CA2778005A1 (en) | 2009-10-26 | 2011-05-12 | Abbott Laboratories | Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| HRP20160422T1 (hr) | 2009-12-23 | 2016-05-20 | Synimmune Gmbh | Protutijela protiv flt3 postupci njihove upotrebe |
| SI2531492T1 (sl) | 2010-02-05 | 2016-08-31 | Heptares Therapeutics Limited | Derivati 1,2,4-triazin-4-amina |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CA2799165C (en) | 2010-05-12 | 2022-04-12 | Steven E. Schutzer | Diagnostic markers for neuropsychiatric disease |
| US20120142701A1 (en) | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| US9242014B2 (en) | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| DK3323830T3 (da) | 2010-06-19 | 2023-09-25 | Memorial Sloan Kettering Cancer Center | Anti-gd2 antibodies |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US20130281304A1 (en) | 2010-08-13 | 2013-10-24 | Andrew P. Feinberg | Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors |
| EP3467101A3 (en) | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| CA2815000C (en) | 2010-10-22 | 2024-05-21 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory t cells programmed to suppress an immune response |
| EA202092589A3 (ru) | 2010-11-08 | 2021-06-30 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| KR20140033029A (ko) | 2011-04-01 | 2014-03-17 | 메모리얼 슬로안-케터링 캔서 센터 | 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| SG195253A1 (en) | 2011-06-03 | 2013-12-30 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| AU2012268036B2 (en) | 2011-06-06 | 2017-04-06 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS | Methods of inhibiting muscle atrophy |
| US20140234342A1 (en) | 2011-06-21 | 2014-08-21 | Innate Pharma | Nkp46-mediated nk cell tuning |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US9910039B2 (en) | 2011-07-01 | 2018-03-06 | Beckman Coulter, Inc. | Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| HUE035751T2 (hu) | 2011-09-02 | 2018-08-28 | Novartis Ag | Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013037118A1 (zh) | 2011-09-16 | 2013-03-21 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| ITMO20110270A1 (it) | 2011-10-25 | 2013-04-26 | Sara Caldrer | Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2 |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN116942833A (zh) | 2011-12-01 | 2023-10-27 | 国立大学法人 东京大学 | 诱导调节性t细胞的增殖或积累的人源细菌 |
| US9439768B2 (en) | 2011-12-08 | 2016-09-13 | Imds Llc | Glenoid vault fixation |
| US9481866B2 (en) | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
| WO2013098797A2 (en) | 2011-12-31 | 2013-07-04 | Kuriakose Moni Abraham | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013131045A1 (en) | 2012-03-02 | 2013-09-06 | The Regents Of The University Of California | Expansion of alloantigen-reactive regulatory t cells |
| US9359447B2 (en) | 2012-03-23 | 2016-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| GB201207297D0 (en) | 2012-04-26 | 2012-06-06 | Senzagen Ab | Analytical methods and arrays for use in the same |
| AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| US9745381B2 (en) | 2012-05-18 | 2017-08-29 | Scott & White Healthcare (Swh) | Bispecific scFv immunofusion (BIf) |
| WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| GB201213571D0 (en) | 2012-07-31 | 2012-09-12 | Univ Leuven Kath | Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| EP2682750A1 (en) | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP6403166B2 (ja) | 2012-08-03 | 2018-10-10 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法 |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| MX2015003114A (es) | 2012-09-10 | 2015-07-06 | Celgene Corp | Metodos para el tratamiento de cancer de mama localmente avanzado. |
| DK2900061T3 (da) | 2012-09-17 | 2020-03-02 | Galectin Therapeutics Inc | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| AU2013329372B2 (en) | 2012-10-08 | 2018-07-12 | St. Jude Children's Research Hospital | Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis |
| NZ630790A (en) | 2012-10-24 | 2016-11-25 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| WO2014122467A1 (en) | 2013-02-06 | 2014-08-14 | Loxbridge Research Llp | Systems and methods for early disease detection and real-time disease monitoring |
| BR112015018882B1 (pt) | 2013-02-19 | 2021-09-14 | Novartis Ag | Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo |
| DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| TW201446794A (zh) | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| US20160046718A1 (en) | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
| US20160031996A1 (en) | 2013-03-14 | 2016-02-04 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| EP2970881A4 (en) | 2013-03-14 | 2017-01-25 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| WO2014151764A2 (en) | 2013-03-15 | 2014-09-25 | Veracyte, Inc. | Methods and compositions for classification of samples |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EA037554B1 (ru) | 2013-03-15 | 2021-04-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Анти-lag-3 связывающие белки |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| US20160122821A1 (en) | 2013-06-10 | 2016-05-05 | Suregene, Llc | Genetic markers of antipsychotic response |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| GB2532672A (en) | 2013-09-09 | 2016-05-25 | Scripps Research Inst | Methods and systems for analysis of organ transplantation |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| WO2015050875A1 (en) | 2013-10-01 | 2015-04-09 | The Regents Of The University Of California | Endometriosis classifier |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| SI3094351T1 (sl) | 2014-01-15 | 2022-05-31 | Kadmon Corporation, Llc | Imunomodulatorna sredstva |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| WO2015112534A2 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099716A1 (en) | 2014-01-28 | 2016-12-07 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| EP3149042B1 (en) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| CN111205268B (zh) | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| PT3215532T (pt) | 2014-11-06 | 2019-12-18 | Hoffmann La Roche | Anticorpos anti-tim3 e métodos de utilização |
| EP3218407A1 (en) | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| EP3227464B1 (en) | 2014-12-05 | 2022-04-20 | Foundation Medicine, Inc. | Multigene analysis of tumor samples |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP3034620A1 (en) | 2014-12-17 | 2016-06-22 | Diaxonhit | Compositions and methods for diagnosing thyroid cancer |
| WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| BR112017015273A2 (pt) | 2015-01-20 | 2018-01-09 | Merial Inc. | compostos e composições antihelmínticos e método de utilizações dos mesmos |
| EP3050570A1 (en) | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF |
| WO2016140974A1 (en) | 2015-03-01 | 2016-09-09 | Novena Therapeutics Inc. | Process for measuring tumor response to an initial oncology treatment |
| CA2978892A1 (en) | 2015-03-06 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| EA201792184A1 (ru) | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| AU2016266942B2 (en) | 2015-05-22 | 2018-10-18 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| CA2988119A1 (en) | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| HUE054149T2 (hu) | 2015-06-04 | 2021-08-30 | Arvinas Operations Inc | Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások |
| WO2016209806A1 (en) | 2015-06-22 | 2016-12-29 | President And Fellows Of Harvard College | Induction of lamina propria regulatory t cells |
| AU2016297249B2 (en) | 2015-07-23 | 2020-11-12 | Inhibrx Biosciences, Inc. | Multivalent and multispecific GITR-binding fusion proteins |
| SI3334431T1 (sl) | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| CA2994346A1 (en) | 2015-08-12 | 2017-02-16 | Medimmune Limited | Gitrl fusion proteins and uses thereof |
| CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| WO2017042337A1 (en) | 2015-09-09 | 2017-03-16 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft | Short-chain fatty acids for use in the treatment of cardiovascular disease |
| WO2017044979A2 (en) | 2015-09-11 | 2017-03-16 | Ventria Bioscience Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
| US10954300B2 (en) | 2015-09-28 | 2021-03-23 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
| US10730835B2 (en) | 2015-09-30 | 2020-08-04 | The United States Of America, As Represented By The Secretary, Health And Human Services | Thalidomide analogs and methods of use |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| US11090373B2 (en) | 2015-12-04 | 2021-08-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antigen-specific T cells for inducing immune tolerance |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| WO2017176958A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| IL290809B2 (en) | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| CN106932576A (zh) | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| JP7585034B2 (ja) * | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
-
2019
- 2019-07-05 AR ARP190101913A patent/AR116109A1/es not_active Application Discontinuation
- 2019-07-08 JP JP2021500409A patent/JP7462606B2/ja active Active
- 2019-07-08 PY PY201901954554A patent/PY1954554A/es unknown
- 2019-07-08 AU AU2019301947A patent/AU2019301947B2/en not_active Ceased
- 2019-07-08 BR BR112021000049-6A patent/BR112021000049B1/pt active IP Right Grant
- 2019-07-08 BR BR122022012745-2A patent/BR122022012745B1/pt active IP Right Grant
- 2019-07-08 WO PCT/IB2019/055807 patent/WO2020012337A1/en not_active Ceased
- 2019-07-08 KR KR1020217003431A patent/KR20210031923A/ko active Pending
- 2019-07-08 CA CA3103674A patent/CA3103674A1/en active Pending
- 2019-07-08 MX MX2021000310A patent/MX2021000310A/es unknown
- 2019-07-08 EP EP19782692.8A patent/EP3820574B1/en active Active
- 2019-07-08 ES ES19782692T patent/ES2963695T3/es active Active
- 2019-07-08 CN CN201980041638.0A patent/CN112334194B/zh active Active
- 2019-07-08 US US16/504,376 patent/US11185537B2/en active Active
- 2019-07-09 UY UY0001038296A patent/UY38296A/es not_active Application Discontinuation
- 2019-07-09 TW TW108124093A patent/TWI830747B/zh active
-
2021
- 2021-10-04 US US17/493,055 patent/US11833142B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020012337A5 (https=) | ||
| JP2021529812A5 (https=) | ||
| JP2021524484A5 (https=) | ||
| JP2022185107A5 (https=) | ||
| JPWO2020012334A5 (https=) | ||
| JP4135318B2 (ja) | 新規なピリミジン−５−カルボキサミド誘導体 | |
| TWI540133B (zh) | 嘧啶衍生物之製造方法 | |
| TWI662023B (zh) | 治療活性化合物及其使用方法（二） | |
| JP2020503299A5 (https=) | ||
| WO2024217557A1 (zh) | 取代的四氢呋喃作为Nav1.8抑制剂 | |
| JP2020505395A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2018138577A5 (https=) | ||
| CN111247152B (zh) | 作为激酶抑制剂的环状亚氨基嘧啶衍生物 | |
| JP2018505880A5 (https=) | ||
| JP2020503297A5 (https=) | ||
| JP2011521968A5 (https=) | ||
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| RU2016103938A (ru) | Модуляторы протеин-тирозинкиназы и способы их применения | |
| EP1256576A1 (en) | Fused imidazolium derivatives | |
| CN105473573A (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| WO2024008185A1 (zh) | 包含sos1抑制剂的药物组合物 | |
| CA2516682A1 (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
| TW201002329A (en) | Quinazoline derivatives | |
| JP2014520108A5 (https=) |